93 related articles for article (PubMed ID: 7651932)
1. Proliferative activity in C-cell hyperplasia and medullary thyroid carcinoma. Evaluation by PCNA immunohistochemistry and AgNORs staining.
Matias-Guiu X; Peiro G; Esquius J; Oliva E; Cabezas R; Colomer A; Prat J
Pathol Res Pract; 1995 Feb; 191(1):42-7. PubMed ID: 7651932
[TBL] [Abstract][Full Text] [Related]
2. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients.
Guyétant S; Josselin N; Savagner F; Rohmer V; Michalak S; Saint-André JP
Mod Pathol; 2003 Aug; 16(8):756-63. PubMed ID: 12920219
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels.
Milone F; Ramundo V; Chiofalo MG; Severino R; Paciolla I; Pezzullo L; Lombardi G; Colao A; Faggiano A
Clin Endocrinol (Oxf); 2010 Jul; 73(1):85-8. PubMed ID: 20039894
[TBL] [Abstract][Full Text] [Related]
4. Polysialic acid of the neural cell adhesion molecule in the human thyroid: a marker for medullary thyroid carcinoma and primary C-cell hyperplasia. An immunohistochemical study on 79 thyroid lesions.
Komminoth P; Roth J; Saremaslani P; Matias-Guiu X; Wolfe HJ; Heitz PU
Am J Surg Pathol; 1994 Apr; 18(4):399-411. PubMed ID: 8141431
[TBL] [Abstract][Full Text] [Related]
5. C-cell hyperplasia and medullary thyroid carcinoma in the rat. An immunohistochemical and ultrastructural analysis.
DeLellis RA; Nunnemacher G; Bitman WR; Gagel RF; Tashjian AH; Blount M; Wolfe HJ
Lab Invest; 1979 Feb; 40(2):140-54. PubMed ID: 431034
[TBL] [Abstract][Full Text] [Related]
6. Her2/neu expression in C-cell hyperplasia and medullary thyroid carcinomas.
Ensinger C; Prommegger R; Kendler D; Gabriel M; Spizzo G; Mikuz G; Kremser R
Anticancer Res; 2003; 23(3B):2241-3. PubMed ID: 12894498
[TBL] [Abstract][Full Text] [Related]
7. Argyrophilic nuclear organizer regions in nasopharyngeal carcinoma and paraneoplastic epithelia.
Chen M; Lee JC; Lo S; Shen J
Head Neck; 2003 May; 25(5):395-9. PubMed ID: 12692877
[TBL] [Abstract][Full Text] [Related]
8. Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities.
Perry A; Molberg K; Albores-Saavedra J
Cancer; 1996 Feb; 77(4):750-6. PubMed ID: 8616768
[TBL] [Abstract][Full Text] [Related]
9. Argyrophilic nucleolar organizer regions in proliferative lesions of the thyroid gland.
Zaczek M; Szot W; Chłap Z
Anal Quant Cytol Histol; 1996 Feb; 18(1):1-8. PubMed ID: 8851102
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry of medullary thyroid carcinoma and C-cell hyperplasia by an affinity-purified anti-human calcitonin antiserum.
Hayashida CY; Alves VA; Kanamura CT; Ezabella MC; Abelin NM; Nicolau W; Bisi H; Toledo SP
Cancer; 1993 Aug; 72(4):1356-63. PubMed ID: 8339225
[TBL] [Abstract][Full Text] [Related]
11. [Expression and clinical significance of the AgNOR and PCNA in Barrett's adenocarcinoma and its precancerous lesions].
Li H; Yao S; Stuart R
Zhonghua Zhong Liu Za Zhi; 1995 Jul; 17(4):286-8. PubMed ID: 7587897
[TBL] [Abstract][Full Text] [Related]
12. Assessment of proliferative activity in Wilms' tumour.
Delahunt B; Farrant GJ; Bethwaite PB; Nacey JN; Lewis ME
Anal Cell Pathol; 1994 Aug; 7(2):127-38. PubMed ID: 7993823
[TBL] [Abstract][Full Text] [Related]
13. C-cell hyperplasia in sporadic and familial medullary thyroid carcinoma.
Yadav M; Agrawal V; Pani KC; Verma R; Jaiswal S; Mishra A; Pandey R
Indian J Pathol Microbiol; 2018; 61(4):485-488. PubMed ID: 30303134
[TBL] [Abstract][Full Text] [Related]
14. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels.
Iacobone M; Niccoli-Sire P; Sebag F; De Micco C; Henry JF
World J Surg; 2002 Aug; 26(8):886-90. PubMed ID: 12016469
[TBL] [Abstract][Full Text] [Related]
15. Succinate dehydrogenase D variants do not constitute a risk factor for developing C cell hyperplasia or sporadic medullary thyroid carcinoma.
Cascon A; Cebrian A; Pollan M; Ruiz-Llorente S; Montero-Conde C; Leton R; Gutierrez R; Lesueur F; Milne RL; Gonzalez-Albarran O; Lucas-Morante T; Benitez J; Ponder BA; Robledo M
J Clin Endocrinol Metab; 2005 Apr; 90(4):2127-30. PubMed ID: 15623805
[TBL] [Abstract][Full Text] [Related]
16. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
[TBL] [Abstract][Full Text] [Related]
17. An improved system for quantifying AgNOR and PCNA in canine tumors.
Hung LC; Pong VF; Cheng CR; Wong FI; Chu RM
Anticancer Res; 2000; 20(5A):3273-80. PubMed ID: 11062753
[TBL] [Abstract][Full Text] [Related]
18. [The study of PCNA expression and AgNORs counting adult-onset laryngeal papilloma].
Wang T; Wang D
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 1998 Aug; 12(8):349-52. PubMed ID: 11263155
[TBL] [Abstract][Full Text] [Related]
19. No relationship between proliferative activity and the MACIS prognostic scoring system in papillary thyroid carcinoma.
Moreira Leite KR; de Araujo VC; Rezende Meirelles MI; Lopes Costa AD; Camara-Lopes LH
Head Neck; 1999 Oct; 21(7):602-5. PubMed ID: 10487946
[TBL] [Abstract][Full Text] [Related]
20. Tumor proliferative fraction in infiltrating duct carcinoma.
Kesari AL; Chellam VG; Nair PP; Madhavan J; Nair P; Nair MK; Pillai MR
Gen Diagn Pathol; 1997 Dec; 143(4):219-24. PubMed ID: 9489954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
